Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 4/20 | 0.40 |
| ▸ | ACE | P12821 | 5/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4622696 | 0.83 | NR1D1 (0.41) | NR1D1MMP9MMP1MMP3ADAM17 | |
| SCHEMBL4622160 | 0.82 | MMP9 (0.39) | ACEMMP9MMP1MMP3ADAM17 | |
| SCHEMBL4649542 | 0.75 | NAMPT (0.41) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL4650285 | 0.74 | KMT2A (0.43) | BCHEACHESIGMAR1 | |
| SCHEMBL12191655 | 0.73 | ACE (0.51) | ACEMMP3 | |
| SCHEMBL28057905 | 0.72 | NR1D1 (0.41) | NR1D1ACEMMP9MMP1MMP3 | |
| SCHEMBL19971615 | 0.70 | BCHE (0.55) | BCHEACHE | |
| SCHEMBL19971616 | 0.70 | BCHE (0.55) | BCHEACHE | |
| SCHEMBL19971611 | 0.70 | BCHE (0.51) | BCHEACHE | |
| SCHEMBL19971612 | 0.70 | BCHE (0.51) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255188-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-16 | — | — | US | claimed |
| US-20080255188-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255188-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | NR1D1 774/4885ACE 328/4885BCHE 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.